18 December 2024NewsAmericasRajiv Nayar, President, HTD Biosystems | Chuck Sholtz, Vice President, Intellectual Property, Nutcracker Therapeutics | Benjamin Pelletier, Partner, Haynes & Boone

WATCH: What are the latest challenges in patenting biologics, biosimilars, and bispecific antibodies?

Speakers from HTD Biosystems, Nutcracker Therapeutics, and Haynes & Boone examine the evolving patent landscape for biologics, biosimilars, and bispecific antibodies, sharing practical strategies and jurisdiction-specific insights.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Week Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Atif Choudhury at achoudhury@lifesciencesipreview.com 


More on this story

Americas
17 June 2026   A cancer diagnostics company has lost its bid to overturn a jury verdict in a major patent dispute that has also spawned parallel proceedings before the Federal Circuit and PTAB.
Americas
15 June 2026   Unanimous jury finds willful infringement, with the possibility of a trebled award and a much larger feud still to come.
Americas
12 June 2026   In a strong response to BioNTech, Moderna argues its next-gen vaccine is built on a fundamentally different design from the German biotech’s—setting up a scrap over whether a key patent should have been granted.